NCT01612676View on ClinicalTrials.gov

Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Septic Shock
Interventions
DRUG

FE 202158

Trial Locations (4)

Unknown

Erasme Hospital Free University of Brussels, Brussels

Saint-Luc University Hospital, Brussels

University Hospital Brussels, Brussels

Hvidovre Hospital, Hvidovre

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY